To determine whether proinflammatory biomarkers are associated with frailty assessed according to functional status, mobility, mental health, and falls over 24 months. DESIGN: Secondary analysis of a 2-year double-blind clinical trial for osteoporosis. SETTING: Nursing homes and assisted living facilities. PARTICIPANTS: Women aged 65 and older with osteoporosis in long-term care (LTC) (N = 178). MEASUREMENTS: Baseline serum concentrations of proinflammatory cytokines and soluble receptors (high sensitivity C-reactive protein (hs-CRP), tumor necrosis factor alpha (TNFa) and its two receptors (TNFa-R1 and TNFa-R2), interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R), IL-10), functional status assessed according to activities of daily living, the Nursing Home Physical Performance Test, gait speed, cognitive status, mental health, and falls. RESULTS: At baseline, older age was moderately associated with higher serum concentrations of hs-CRP (correlation coefficient (r) = 0.22), TNFa-R1 (r = 0.36), TNFa-R2 (r = 0.34), and IL-10 (r = 0.16) (all P < .05). Frail participants had significantly higher hs-CRP, TNFa-R1, TNFa-R2, IL-6, and IL-6-sR levels (all P < .05) than those nonfrail participants. Higher baseline hs-CRP and IL-6 levels were associated with worse physical performance and gait speed at 12 months independent of age, zoledronic acid use, and comorbidity (|r| = 0.25-0.30; all P < .05). Inflammatory markers were not significantly associated with incident falls. CONCLUSIONS: Higher proinflammatory biomarker levels are associated with frailty and poorer function and mobility in older women residing in LTC facilities.
F
railty is a prevalent geriatric syndrome that encompasses a variety of phenotypic characteristics in old age, including muscle weakness, bone fragility, and increased fall risk, that result in vulnerability to functional decline and mortality. [1] [2] [3] [4] Frailty is characterized by multiorgan system dysfunction and maladaptive responses to stressors, leading to functional decline and other serious adverse health outcomes such as infection, delirium, and trauma. 5, 6 Although there is not a single operational definition of frailty, 7 several definitions have been proposed, most notably the frailty phenotype described by Fried 1 and the frailty index proposed by Rockwood. [8] [9] [10] The Fried model uses five traits (weight loss, weakness, poor endurance or exhaustion, slowness, low physical activity) to define an underlying physiological state of multisystem decline, with three of these required for a positive frailty phenotype. 1 The Rockwood model examines the proportion of accumulation of deficits such as symptoms, signs, functional impairments, and laboratory abnormalities, the composite of which reflects the severity of frailty-associated morbidity and mortality. [8] [9] [10] Much of the information about frailty in older adults has been gleaned through investigations of community-dwelling older adults taking part in large epidemiological studies. [11] [12] [13] [14] The characterization of frailty in older adults residing in long-term care (LTC) and the applicability of these criteria to this special population are even less well defined. 15 Another phenotypic characteristic of old age that has received attention in recent years is the subclinical chronic inflammatory state seen in older adults. Investigators have used the term "inflammaging," defined as "a global reduction in the capability to cope with a variety of stressors and a concomitant progressive increase in the proinflammatory status," 16 to describe this phenomenon. Several studies have demonstrated that the innate and adaptive components of the immune system exhibit dysfunction in older adults considered frail according to the previously discussed definitions.
proinflammatory markers such as interleukin-6 (IL-6) and C-reactive protein (CRP) are high in older adults [20] [21] [22] and have been linked to a number of conditions, particularly cardiovascular disease, 23, 24 although fewer studies have examined the effect of high proinflammatory markers specifically on frailty. A recent metaanalysis reported that, in cross-sectional studies, frail and prefrail participants had significantly higher CRP and IL-6 levels than robust (nonfrail) participants, although the three longitudinal studies included in this metaanalysis did not bear out this association. 25 The studies included in this metaanalysis, among others that have also explored the relationship between proinflammatory markers and measures of frailty such as function, mobility, mental health, and falls, 20, 21, 26, 27 primarily included community-dwelling older adults. There are fewer data regarding this relationship in older adults who reside in LTC facilities, who are often older and frailer than those who reside in the community at baseline.
The Zoledronic acid in frail Elders to STrengthen bone study demonstrated that a one-time infusion of zoledronic acid positively affected spine and hip bone mineral density (BMD) and bone turnover in frail female LTC residents, over 2 years. 28 Zoledronic acid has been shown to reduce the rate of new hip fractures and improve survival in individuals who had undergone repair of a prior hip fracture. 29 Intravenous bisphosphonates such as zoledronic acid have been known to activate a transient acute-phase response characterized by fever, myalgias, and other influenza-like symptoms in the 24 to 36 hours after infusion and can be associated with a transient fall in the number of circulating lymphocytes. 30 Other studies have reported a reduction in the number of gamma-delta T lymphocytes 1 year after exposure to zoledronic acid in individuals with osteoporosis, 31 although there is a dearth of additional literature regarding the potential effects of intravenous bisphosphonate exposure on other immunoregulatory markers. The present study tested the hypothesis that high serum levels of proinflammatory biomarkers were associated with greater frailty as assessed according to functional status, mobility, mental health, and falls in the Zoledronic acid in frail Elders to STrengthen bone cohort. The aims of this investigation were to determine whether baseline measurement of serum proinflammatory marker levels would serve as a potential marker for frailty assessed according to functional status (activities of daily living (ADLs: eating, toileting, transferring, bathing, dressing), instrumental activities of daily living (IADLs: shopping, meal preparation, heavy housework), Nursing Home Physical Performance Test (PPT)), mobility, mental health, and history of falls and to examine whether baseline levels of proinflammatory markers were associated with functional decline and incident falls over time.
METHODS

Study Design
This prospective secondary analysis reports baseline inflammatory cytokine levels and changes in measures of frailty over 24 months in 178 women with inflammatory biomarker data enrolled in a double-blind, placebo-controlled, randomized clinical trial. 28 Briefly, participants were randomly assigned to active treatment with a one-time infusion of zoledronic acid 5 mg or matching placebo, as previously described.
Participants
Women aged 65 and older residing in LTC facilities in the greater Pittsburgh area were screened for this study and enrolled if they had low BMD, defined as a T-score of 2.0 standard deviations or more below the mean or previous adult fragility fracture. 28 The University of Pittsburgh institutional review board and the Pennsylvania Department of Health approved the protocol, and participants provided written informed consent before participation.
Inflammatory Biomarkers
Nonfasting serum samples were collected in the morning, processed, frozen at À80°C, and run using the same assays to reduce interbatch variability. Serum biomarkers known to play a role in the inflammatory response that have been previously examined in large epidemiological studies of community-dwelling adults were analyzed to determine their potential association with incident fracture risk. 26, 27 These included high-sensitivity CRP (hs-CRP), tumor necrosis factor alpha (TNFa) and its receptors (TNFa-R1 and TNFa-R2), interleukin 6 (IL-6) and its soluble receptor (sIL-6R), and IL-10. Serum cytokine and soluble cytokine receptor levels were measured in duplicate using enzymelinked immunosorbent assay (ELISA) kits. The detectable limit was 1.9 ng/mL for the hs-CRP ELISA (ALPCO Diagnostics, Salem, NH), 0.7 pg/mL for IL-6 (Human IL-6 Ultra-Sensitive Kit; Meso Scale Discovery, Rockville, MD), 10 pg/mL for sIL-6R (DR600 kit; R&D Systems, Inc., Minneapolis, MN), 0.3 pg/mL for TNFa (Human TNFa Ultra-Sensitive Kit; Meso Scale Discovery), 3 pg/mL for TNFa-R1 (DRT100 kit; R&D Systems, Inc.), 1 pg/mL for TNFa-R2 (DRT200 kit; R&D Systems, Inc.), and 23.4 pg/ mL for IL-10 (Human IL-10 Ultra-Sensitive Kit; Meso Scale Discovery). Assays of blind duplicates collected for the participants yielded average interassay coefficients of variation of 2.22% for hs-CRP, 2.79% for IL-6, 3.54% for sIL-6R, 7.07% for TNFa, 8.95% for TNFa-R1, 5.93% for TNFa-R2, and 4.31% for IL-10.
Outcomes
Outcome measures of function, mobility, cognition, and mental health were used to describe a phenotypic picture of frailty in the cohort, as previously described. 28, 32 ADLs, IADLs, gait speed, and the PPT 33 were used to examine function and mobility. Cognitive status was assessed using the Short Portable Mental Status Questionnaire (SPMSQ), 34 and mental health was evaluated using the Patient Health Questionnaire (PHQ-9). 35 A modified version of the Fried frailty index 1 was developed (Table 1) to categorize participants as nonfrail (0 frailty criteria), prefrail (1-2 frailty criteria), and frail (≥3 frailty criteria). Additional outcome variables of interest included history of falls at baseline as determined according to self-report (history) and in the Minimum Data Set, charts, and medical records at the LTC facilities (any or recurrent) and incident falls over the course of the study period. Comorbidity was assessed using the Duke comorbidity index. 36 
Statistical Analysis
Statistical analysis was performed using SAS version 9.3 (SAS Institute, Inc., Cary, NC). Appropriate descriptive statistics were used to summarize baseline participant characteristics according to frailty category. Medians and interquartile ranges were used for skewed continuous variables measuring timed performances and inflammatory markers. Age, treatment group (zoledronic acid, placebo), and comorbidity-adjusted partial correlation coefficients (r) were used to measure the association between serum inflammatory markers and each continuous variable representing outcomes at baseline and change over time. Means comparisons using analysis of variance (ANOVA) were used to determine whether serum inflammatory markers differed between frailty categories. Timed performance (sit-to-stand, walking) and inflammatory markers were log transformed before correlation analyses and ANOVA.
RESULTS
Baseline Characteristics and Associations
The mean age of participants at baseline was 85.6 AE 5.0, 42% had experienced at least one fall at baseline (Table 2) , and 63.5% reported a fracture as an adult.
Eleven participants were classified as nonfrail, 53 as prefrail, and 114 as frail using the modified version of the Fried Frailty Index (Table 2 ). Frail participants were older and had lower ADL, IADL, PPT, and SPMSQ scores than those who were not frail. Walk time, sit-to-stand time, and gait speed were slower in frail participants, who also had worse PHQ-9 scores and were more likely to have had prior falls (Table 2) . Frail participants had significantly higher hs-CRP, TNFa-R1, TNFa-R2, IL-6, and IL-6-sR levels than those who were nonfrail, and those classified as prefrail had significantly higher TNFa-R1 and TNFa-R2 levels than those who were nonfrail (all P < .05, Figure 1 ). Frail participants had significantly higher hs-CRP and IL-6 levels than prefrail participants (both P < .05). At baseline, age was moderately associated with higher serum hs-CRP, TNFa-R1, TNFa-R2, and IL-10 concentrations (r = 0.16-0.36; all P < .05). Participants who had experienced at least one fall had higher serum TNFa-R2 concentrations (P = .048), but the difference was slightly attenuated after controlling for age and comorbidity (P = .07).
Associations of Baseline Inflammatory Markers and Future Function Over Time
Higher baseline hs-CRP and IL-6 levels were associated with worse ADL performance, physical performance, walk time, and gait speed at 12 months independent of age, zoledronic acid use, and baseline comorbidity (|r| = 0.19-0.32; all P < .05). Higher IL-6 was associated with physical performance, walk time, and gait speed at 12 months (|r| = 0.23-0.29; all P < .05), but these associations generally did not persist at 24 months, with the exception of IADLs and IL-6 (r = À0.30; P < .05). The strength of associations was in the mild to moderate range, as indicated by the magnitudes of correlations (Table 3 ). Controlling for age, comorbid burden, and zoledronic acid use, inflammatory markers did not significantly differ between incident fallers (median 2.4, interquartile range (IQR) 1.6-4.8) and nonfallers (median 2.0, IQR 1.2-3.2) (P = .10), although there was a suggestive difference in that higher IL-6 levels were observed in incident fallers, though this did not achieve statistical significance.
In terms of changes in functional status from baseline to follow-up, higher baseline IL-10 level was moderately associated with decline in IADL score over 12 months (r = À0.20, P < .05) and higher baseline TNFa levels with declines in walking performance (|r| = 0.22-24; P < .05), independent of age, comorbid burden, and zoledronic acid use. TNFa-R2 was associated with IADL decline over 24 months (r = À0.22; P < .05). 
DISCUSSION
This prospective secondary analysis of older women in LTC facilities suggests that those with higher proinflammatory cytokine levels, including hs-CRP and IL-6, at baseline had poorer baseline and 12-and 24-month functional measures, as well as greater declines in these functional measures over time, independent of baseline comorbidity, although a history of falls at baseline and incident falls were not associated with higher proinflammatory cytokine levels after adjustment for comorbid conditions. Although many studies have reported the negative effects of "inflammaging," 16, 24, 37, 38 few data are available on the effect of the subclinical chronic inflammation seen in the frailest older adults on their global functional state, which the authors of the current study consider to be inclusive not only of ADLs, but also mobility, gait, number of falls, mood, and cognitive function. An analysis of the Health, Aging, and Body Composition (HealthABC) Study, consisting of a large cohort of community-dwelling older adults, found that participants who developed incident mobility limitation during the study period had significantly higher serum CRP, IL-6, and TNFa levels at baseline (all P < .001). 39 Even after adjustment for incident severe illness and other comorbidities, participants with high levels of one or two inflammatory markers were at greater risk of developing incident mobility limitation than those with no high levels (relative risk (RR) = 1.32 for one, RR = 1.37 for two). Participants with high serum levels of all three markers (CRP, IL-6, TNFa) had an even higher risk of developing incident mobility limitation (RR = 1.84). 39 The current study is unique in that the effect of high inflammatory markers at baseline on multiple measures of function was examined in women residing in LTC who were known to be frail at baseline, with a number of functional limitations.
In the Study of Osteoporotic Fractures, which included older community-dwelling women and used similar inflammatory markers, women with a high inflammatory burden (those in the highest quartile) had a greater risk of hip fracture over approximately 6 years than those without a high inflammatory burden. 40 In the Women's Health Initiative, from a nested case-control study, high TNFa-R1, TNFa-R2, and IL-6-sR levels were associated with greater risk of hip fracture over a median follow-up of 7 years. 27 Although the current study was smaller and shorter in duration than those studies, the cytokine trends found with higher levels of the TNF-a receptors and the soluble IL-6 receptor being associated with frailty and worsening function support potential explanation for greater risk of hip fractures in the cohorts followed in these prior studies.
There are some general limitations to this study. Because the study population consisted of frail elderly LTC facility residents, selected outcomes were limited to assessments that could be performed at each facility. With regard to the assessment of frailty using a modified Fried frailty index, there may have been implicit bias introduced into the results based on these modifications, as explored previously in a systematic review. 41 Although the associations between higher proinflammatory cytokine levels and markers of frailty were adjusted for comorbidity, participants who had a diagnosis characterized by chronic inflammation (e.g., rheumatoid arthritis, systemic lupus erythematosus) were not differentiated from those who had taken antiinflammatory agents such as TNFa inhibitors. Additionally, data were not available regarding inflammatory biomarkers at follow-up time points in these individuals, which prevents the potential effect of zoledronic acid exposure on inflammatory biomarkers over time from being assessed. For both of these reasons, the ability to focus on clinically significant outcomes related to the subclinical chronic inflammation seen in older adults may have decreased relative to had we been able to incorporate this data, although excluding the 18 (10%) participants who were taking systemic glucocorticoids at baseline did not significantly change the results. Moreover, because this was an ancillary and exploratory analysis mainly to generate hypotheses rather than draw definitive conclusions, strict multiplicity corrections for obtaining statistical significance were not considered. A longer study would have been better able to examine effects of inflammation on frailty markers over time, which may be valuable given the chronicity of subclinical inflammation seen in frail older adults. Another limitation is that men were not included in this study, making the results less generalizable to the population of older adults as a whole. Finally, this was a secondary analysis of a clinical trial that examined the effect of zoledronic acid on skeletal integrity rather than one specifically designed prospectively for the present investigation. Despite these limitations, there are several important strengths to this study. For instance, the Fried frailty criteria do not include other factors such as declines in cognition, mood disorders, and poor function, all of which are common findings in LTC residents. Inclusion of these additional domains in the current analysis allowed for a fuller characterization of a frailty phenotype while still remaining clinically feasible and relevant. In addition, the assay methods used to evaluate proinflammatory cytokine levels were state of the art. In particular, soluble receptor levels of some of these cytokines were measured, which is an important distinction because previous studies have shown that high soluble receptor levels for these cytokines are more constant and may be more representative of chronic and severe inflammation. [42] [43] [44] Some of these soluble cytokine receptors (e.g., TNFa-R1) have been shown in large cohort studies to be associated with morbidity, independent of their corresponding ligands. 45 Finally, although large epidemiological studies have examined inflammatory biomarkers in community-dwelling older adults and had excluded frail older adults in LTC, it was possible to examine these associations by performing the study on site in the LTC facilities.
In summary, higher proinflammatory biomarker levels were associated with decline in function and mobility independent of baseline comorbidity in frail female LTC residents. Additional confirmatory studies are needed in broader target populations that include men.
